Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts benefit from h...
主要な著者: | Irlam-Jones, J, Eustace, A, Denley, H, Choudhury, A, Harris, A, Hoskin, P, West, C |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Cancer Research UK
2016
|
類似資料
-
A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients
著者:: Yang, L, 等
出版事項: (2017) -
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
著者:: Eustace, A, 等
出版事項: (2013) -
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
著者:: Eustace, A, 等
出版事項: (2013) -
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
著者:: Eustace, A, 等
出版事項: (2013) -
Impact of Hypoxia-Induced miR-210 on Pancreatic Cancer
著者:: Mutian Lian, 等
出版事項: (2023-12-01)